Levodopa/Carbidopa Mylan (Levodopa, Anhydrous Carbidopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, the neurotransmitter deficient in Parkinson's disease. Carbidopa blocks peripheral conversion, ensuring more levodopa reaches the brain and minimizing peripheral side effects.

The exact dosage and dosing schedule are determined by the prescribing clinician based on the individual patient's condition, response, and tolerability. Patients should follow the prescriber's instructions and not adjust the dose on their own.

Safety data for Levodopa/Carbidopa in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Levodopa/Carbidopa is considered the most effective symptomatic therapy for Parkinson's disease, directly replenishing dopamine. Other classes, such as dopamine agonists or MAO‑B inhibitors, may be used as adjuncts or in early disease, but they generally provide less robust motor improvement than levodopa‑based regimens.

Store the tablets at ambient temperature, below 25 °C, in the original container. Keep them away from excess moisture and direct sunlight to maintain product stability throughout its shelf life.

Levodopa/Carbidopa Mylan is taken orally, usually with a glass of water. It may be taken with or without food, but high‑protein meals can interfere with absorption, so clinicians often advise spacing the dose from protein‑rich meals.

Serious risks include the development of dyskinesias (involuntary movements), psychiatric effects such as hallucinations or confusion, and rare hypertensive crises when combined with certain monoamine oxidase inhibitors. Patients should be monitored regularly for these complications.

Patients with known hypersensitivity to levodopa, carbidopa, or any excipients should avoid the product. It is also contraindicated in individuals taking non‑selective MAO inhibitors or those with narrow‑angle glaucoma, unless specifically directed by a physician.